The future of genetic medicine appears promising, with cases like baby KJ demonstrating gene therapy's potential to fix genetic flaws. However, recent incidents have raised safety concerns. In China, two deaths occurred in investigator-initiated trials (IITs) with less regulatory oversight: a six-year-old girl died in an experimental CRISPR trial, and a young boy with Duchenne muscular dystrophy died after gene therapy. In the U.S., a child developed a brain tumor likely caused by the viral vector used in treatment four years earlier, though it was surgically removed.